Jingwei Tian

Dr. Jingwei Tian


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
WZWei Zhu
Wei Zhu
LYLiang Ye
Liang Ye
JZJianzhao Zhang
Jianzhao Zhang
PYPengfei Yu
Pengfei Yu
HWHongbo Wang
Hongbo Wang
JTJingwei Tian
Jingwei Tian
PFKFB3 (6-phosphofructo-2-kinase) synthesizes fructose 2,6-bisphosphate (F2,6P2), which is an allosteric activator of 6-phosphofructo-1-kinase (PFK-1), the rate-limiting enzyme of glycolysis. Overexpression of the PFKFB3 enzyme leads to high glycolytic metabolism, which is required for cancer cells to survive in the harsh tumor microenvironment. The objective of this study was to investigate the antitumor activity of PFK15 (1-(4-pyridinyl)-3-(2-quinolinyl)-2-propen-1-one), a small molecule inhibitor of PFKFB3, against gastric cancer and to explore its potential mechanisms. The effects of PFK15 on proliferation, apoptosis and cell cycle progression in gastric cancer cells were evaluated by cytotoxicity and apoptosis assays, flow cytometry, and western blotting. In addition, the invasion inhibition effects of PFK15 were measured by transwell invasion assay and western blot analysis, and a xenograft tumor model was used to verify the therapeutic effect of PFK15 in vivo. Results showed that PFK15 inhibited the proliferation, caused cell cycle arrest in G0/G1 phase by blocking the Cyclin-CDKs/Rb/E2F signaling pathway, and induced apoptosis through mitochondria in gastric cancer cells. Tumor volume and weight were also significantly reduced upon intraperitoneal injection with PFK15 at 25 mg/kg. In addition, PFK15 inhibited the invasion of gastric cancer cells by downregulating focal adhesion kinase (FAK) expression and upregulating E-cadherin expression. Taken together, our findings indicate that PFK15 is a promising anticancer drug for treating gastric cancer.

16 January 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
CLChunmei Li
Chunmei Li
RHRui Han
Rui Han
LKLe Kang
Le Kang
JWJianping Wang
Jianping Wang
YGYonglin Gao
Yonglin Gao
JTJingwei Tian
Jingwei Tian
Pirfenidone (PFD), an anti-fibrotic small molecule drug, is used to treat fibrotic diseases, but its effects on myocardial infarction (MI)-induced cardiac fibrosis are unknown. The aim of this study was to determine the effects of PFD on MI-induced cardiac fibrosis and the possible underlying mechanisms in rats. After establishment of the model, animals were administered PFD by gavage for 4 weeks. During the development of MI-induced cardiac fibrosis, we found activation of a positive feedback loop between the angiotensin II type 1 receptor (AT1R)/phospho-p38 mitogen-activated protein kinase (p38 MAPK) pathway and renin-angiotensin system (RAS), which was accompanied by down-regulation of liver X receptor-α (LXR-α) expression. PFD attenuated body weight, heart weight, left ventricular weight, left ventricular systolic pressure, and ±dp/dtmax changes induced by MI, which were associated with a reduction in cardiac fibrosis, infarct size, and hydroxyproline concentration. Moreover, PFD inhibited the AT1R/p38 MAPK pathway, corrected the RAS imbalance [decreased angiotensin-converting enzyme (ACE), angiotensin II, and angiotensin II type 1 receptor expression, but increased ACE2 and angiotensin (1-7) activity and Mas expression] and strongly enhanced heart LXR-α expression. These results indicate that the cardioprotective effects of PFD may be due, in large part, to controlling the feedback loop of the AT1R/p38 MAPK/RAS axis by activation of LXR-α.

9 July 2014 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JTJingwei Tian
Jingwei Tian
FZFangxi Zhang
Fangxi Zhang
JCJucan Cheng
Jucan Cheng
SGShuren Guo
Shuren Guo
PLPinglan Liu
Pinglan Liu
HWHongbo Wang
Hongbo Wang
Adhyperforin is a novel constituent of Hypericum perforatum L., but its antidepressant-like activity remains unclear. To explore that, several well-validated animal models of depression as well as neurotransmitter reuptake and transporter binding assays were conducted. The results showed adhyperforin could reduce the immobility time of mice in the forced swimming test and tail suspension assay, antagonize the behaviors induced by reserpine, and have no effect on locomotor activity. Furthermore, following establishment of a chronic unpredictable mild stress model, adhyperforin increased the number of crossings and rearings in rats in the open field test and increased the sucrose consumption. Finally, adhyperforin inhibited uptake of serotonin, norepinephrine, and dopamine, and displayed robust binding affinities for the serotonin and norepinephrine transporters. Overall, the current study provides the first evidence that adhyperforin is a novel, active ingredient of Hypericum perforatum L. with robust antidepressant-like activity.

29 August 2016 in Journal of Agricultural and Food Chemistry
Verified
Journal Article
Closed access
QLQiaofeng Liu
Qiaofeng Liu
JTJingwei Tian
Jingwei Tian
YXYanan Xu
Yanan Xu
CLChunmei Li
Chunmei Li
XMXiangjing Meng
Xiangjing Meng
FFFenghua Fu
Fenghua Fu

18 February 2014 in Planta Medica
Verified
Journal Article
Closed access
PDF file
HZHaibo Zhu
Haibo Zhu
LZLibo Zou
Libo Zou
JTJingwei Tian
Jingwei Tian
FLFei Lin
Fei Lin
JHJie He
Jie He
JHJian Hou
Jian Hou
Sodium formononetin-3′-sulphonate is a derivative of the plant isoflavone formononetin. The present study aimed to investigate the neuroprotective and angiogenesis effects of sodium formononetin-3′-sulphonate in vivo and in vitro. Treatment with sodium formononetin-3′-sulphonate (3, 7.5, 15, and 30 mg/kg, intravenous injection) could protect the brain from ischemia and reperfusion injury by improving neurological function, suppressing cell apoptosis, and increasing expression levels of vascular endothelial growth factor and platelet endothelial cell adhesion molecule 1 by middle cerebral artery occlusion. Treatment with sodium formononetin-3′-sulphonate (10 and 20 µg/mL) significantly increased cell migration, tube formation, and vascular endothelial growth factor and platelet endothelial cell adhesion molecule levels in human umbilical vein endothelial cells. Our results suggest that sodium formononetin-3′-sulphonate provides significant neuroprotective effects against cerebral ischemia and reperfusion injury in rats, and improves cerebrovascular angiogenesis in human umbilical vein endothelial cells. The protective mechanisms of sodium formononetin-3′-sulphonate may be attributed to the suppression of cell apoptosis and improved cerebrovascular angiogenesis by promoting vascular endothelial growth factor and platelet endothelial cell adhesion molecule expression.

14 February 2011 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
SZShumin Zhang
Shumin Zhang
XTXuexi Tang
Xuexi Tang
JTJingwei Tian
Jingwei Tian
CLChunmei Li
Chunmei Li
GZGuanbo Zhang
Guanbo Zhang
ZZZunting Zhang
Zunting Zhang